Male Reproductive Cancers Resource Center
The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."
Scientists are testing immune checkpoint proteins, CD8 T cell clonal expansion, mutational load, and PSA levels as predictive biomarkers for prostate cancer immunotherapy outcomes.
Male Reproductive Cancers News
Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.
More Male Reproductive Cancers Resources
This fact sheet answers some common questions about prostate cancer, bone scan, and metastasis.
This fact sheet reviews current prostate cancer screening tests, guidelines, PSA, and risk factors.
This fact sheet provides information on symptoms, pain, causes, and treatments for testicular, testicle cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible
- Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future
- NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib